×
About 54,424 results

ALLMedicine™ Psoriasis Center

Research & Reviews  24,107 results

Covid-19 pandemic and the skin.
https://doi.org/10.1111/ijd.15189
International Journal of Dermatology References; Drenovska K, Schmidt E et. al.

Sep 21st, 2020 - In the beginning of the COVID-19 outbreak, skin manifestations, if present, were not paid enough attention. Then, the focus moved toward the impact of the prolonged use of personal protective measures in both healthcare workers and patients. In th...

Visual Dermatology: Rupioid Psoriasis.
https://doi.org/10.1177/1203475420961367
Journal of Cutaneous Medicine and Surgery; Jimenez-Cauhe J, Diaz-Guimaraens B

Sep 21st, 2020 - Visual Dermatology: Rupioid Psoriasis.|2020|Jimenez-Cauhe J,Diaz-Guimaraens B,|

Periodontitis and the impact of oral health on the quality of life of psoriatic individ...
https://doi.org/10.1007/s00784-020-03600-1
Clinical Oral Investigations; Costa AA, Cota LOM et. al.

Sep 21st, 2020 - To evaluate the periodontal condition and the impact of oral health on the quality of life (OHRQL) among individuals with and without psoriasis. This case-control study comprised 295 individuals with psoriasis and 359 controls. A full mouth examin...

Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive manag...
https://doi.org/10.1016/j.jaad.2020.09.037
Journal of the American Academy of Dermatology; Lebwohl M, Kircik L et. al.

Sep 20th, 2020 - Topical psoriasis treatment relies on a reactive, rather than long-term proactive, approach to disease relapse. Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionat...

Long-term efficacy of certolizumab pegol for psoriasis.
https://doi.org/10.1111/bjd.19537
The British Journal of Dermatology References; Johnson MC, Heron CE et. al.

Sep 20th, 2020 - Long-term efficacy of certolizumab pegol for psoriasis.|2020|Johnson MC,Heron CE,Feldman SR,|

see more →

Guidelines  179 results

Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394160/
Postepy Dermatol Alergol; Michalska

Jul 13th, 2020 - Psoriasis is an autoimmune, chronic disease determined by environmental and genetic factors. The occurrence of psoriasis is accompanied by metabolic diseases, cardiovascular diseases (CVD) and depression, disturbances on interpersonal interactions...

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211212/
Rheumatology and Therapy; Dal Bello G

Apr 16th, 2020 - Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory spondyloarthropathy associated with psoriasis. PsA is frequently associated with metabolic disorders including, obesity, metabolic syndrome, and diabetes mellitus (DM). Type 2 DM ...

Genital Ulcers: Differential Diagnosis and Management
https://www.aafp.org/afp/2020/0315/p355.html
American Family Physician; Roett MA,et al

Mar 14th, 2020 - Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex...

Genital Ulcers: What Causes Them?
https://www.aafp.org/afp/2020/0315/p355-s1.html
American Family Physician;

Mar 14th, 2020 - They are usually caused by sexually transmitted infections (STIs), most commonly herpes, less commonly syphilis, and rarely chancroid (SHAN-kroid). For men who have sex with men, syphilis is the most common cause. Rare cases of mononucleosis (MAA-...

Prevalence and severity of fatigue in psoriasis and psoriatic arthritis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247072/
Advances in Dermatology and Allergology; Krajewska-Wlodarczyk M

Mar 8th, 2020 - The evaluation of incidence and severity of fatigue as well as the influence of selected factors on fatigue in patients with psoriasis and psoriatic arthritis (PsA).

see more →

Drugs  1,215 results see all →

Clinicaltrials.gov  25,927 results

Covid-19 pandemic and the skin.
https://doi.org/10.1111/ijd.15189
International Journal of Dermatology References; Drenovska K, Schmidt E et. al.

Sep 21st, 2020 - In the beginning of the COVID-19 outbreak, skin manifestations, if present, were not paid enough attention. Then, the focus moved toward the impact of the prolonged use of personal protective measures in both healthcare workers and patients. In th...

Visual Dermatology: Rupioid Psoriasis.
https://doi.org/10.1177/1203475420961367
Journal of Cutaneous Medicine and Surgery; Jimenez-Cauhe J, Diaz-Guimaraens B

Sep 21st, 2020 - Visual Dermatology: Rupioid Psoriasis.|2020|Jimenez-Cauhe J,Diaz-Guimaraens B,|

Periodontitis and the impact of oral health on the quality of life of psoriatic individ...
https://doi.org/10.1007/s00784-020-03600-1
Clinical Oral Investigations; Costa AA, Cota LOM et. al.

Sep 21st, 2020 - To evaluate the periodontal condition and the impact of oral health on the quality of life (OHRQL) among individuals with and without psoriasis. This case-control study comprised 295 individuals with psoriasis and 359 controls. A full mouth examin...

Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive manag...
https://doi.org/10.1016/j.jaad.2020.09.037
Journal of the American Academy of Dermatology; Lebwohl M, Kircik L et. al.

Sep 20th, 2020 - Topical psoriasis treatment relies on a reactive, rather than long-term proactive, approach to disease relapse. Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionat...

Long-term efficacy of certolizumab pegol for psoriasis.
https://doi.org/10.1111/bjd.19537
The British Journal of Dermatology References; Johnson MC, Heron CE et. al.

Sep 20th, 2020 - Long-term efficacy of certolizumab pegol for psoriasis.|2020|Johnson MC,Heron CE,Feldman SR,|

see more →

News  2,779 results

Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394160/
Postepy Dermatol Alergol; Michalska

Jul 13th, 2020 - Psoriasis is an autoimmune, chronic disease determined by environmental and genetic factors. The occurrence of psoriasis is accompanied by metabolic diseases, cardiovascular diseases (CVD) and depression, disturbances on interpersonal interactions...

India's Biocon secures approval to use drug on coronavirus patients
https://www.reuters.com/article/us-india-biocon/indias-biocon-secures-approval-to-use-drug-on-coronavirus-patients-idUSKCN24C0K8

Jul 11th, 2020 - FILE PHOTO: India's Biocon Ltd Chairman and Managing Director Kiran Mazumdar-Shaw speaks during the Forbes Global CEO Conference in Kuala Lumpur September 13, 2011. REUTERS/Bazuki Muhammad/File Photo NEW DELHI (Reuters) - India’s Biocon Ltd has re...

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211212/
Rheumatology and Therapy; Dal Bello G

Apr 16th, 2020 - Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory spondyloarthropathy associated with psoriasis. PsA is frequently associated with metabolic disorders including, obesity, metabolic syndrome, and diabetes mellitus (DM). Type 2 DM ...

Genome study examines heritability of psoriatic disease subtypes
https://www.mdedge.com/rheumatology/article/220146/psoriatic-arthritis/genome-study-examines-heritability-psoriatic-disease?channel=39313
Bianca Nogrady

Apr 2nd, 2020 - Genetic variation plays a greater role in the phenotype of cutaneous psoriasis, compared with psoriatic arthritis or psoriasis vulgaris, according to a study published in Scientific Reports. Psoriatic disease is known to have a strong genetic basi.

FDA approves ixekizumab for pediatric plaque psoriasis
https://www.mdedge.com/jcomjournal/article/219818/pediatrics/fda-approves-ixekizumab-pediatric-plaque-psoriasis?channel=325
Christopher Palmer

Mar 30th, 2020 - The Food and Drug Administration has approved ixekizumab for treatment of moderate to severe plaque psoriasis in patients aged 6-17 years, according to an announcement from Lilly. Patients need to be candidates for systemic therapy or phototherapy.

see more →

Patient Education  217 results see all →